Pfizer (NYSE:PFE – Get Rating) was downgraded by UBS Group from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They currently have a $47.00 target price on the biopharmaceutical company's stock, down from their previous target price of $55.00. UBS Group's price target suggests a potential upside of 7.33% from the company's previous close.
Several other research analysts have also recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Pfizer from $51.00 to $53.00 and gave the stock an "equal weight" rating in a report on Wednesday, December 14th. Bank of America cut shares of Pfizer from a "buy" rating to a "neutral" rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. The Goldman Sachs Group upgraded shares of Pfizer from a "neutral" rating to a "buy" rating and boosted their target price for the company from $47.00 to $60.00 in a research note on Tuesday, December 13th. SVB Leerink boosted their target price on shares of Pfizer from $48.00 to $49.00 and gave the company a "market perform" rating in a research note on Thursday, November 3rd. Finally, Barclays boosted their target price on shares of Pfizer from $44.00 to $49.00 and gave the company an "equal weight" rating in a research note on Wednesday, November 2nd. Eight investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $52.33.
Get Pfizer alerts:Pfizer Trading Down 1.0 %
NYSE:PFE opened at $43.79 on Thursday. Pfizer has a one year low of $41.44 and a one year high of $56.32. The company has a market cap of $245.81 billion, a PE ratio of 8.49, a PEG ratio of 1.11 and a beta of 0.67. The firm has a 50-day moving average of $49.54 and a 200-day moving average of $48.01. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37.
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.31. Pfizer had a net margin of 29.81% and a return on equity of 43.95%. The business had revenue of $22.64 billion for the quarter, compared to analysts' expectations of $21.04 billion. As a group, equities research analysts expect that Pfizer will post 6.47 EPS for the current fiscal year.Institutional Trading of Pfizer
A number of institutional investors have recently modified their holdings of the business. Barnes Pettey Financial Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at approximately $208,000. MV Capital Management Inc. increased its holdings in Pfizer by 3.2% during the 4th quarter. MV Capital Management Inc. now owns 49,049 shares of the biopharmaceutical company's stock worth $2,513,000 after acquiring an additional 1,514 shares during the period. West Branch Capital LLC increased its holdings in Pfizer by 1.6% during the 4th quarter. West Branch Capital LLC now owns 53,968 shares of the biopharmaceutical company's stock worth $2,765,000 after acquiring an additional 830 shares during the period. Natixis Advisors L.P. increased its holdings in Pfizer by 61.3% during the 4th quarter. Natixis Advisors L.P. now owns 2,147,607 shares of the biopharmaceutical company's stock worth $110,043,000 after acquiring an additional 816,561 shares during the period. Finally, Beacon Capital Management LLC increased its holdings in Pfizer by 3.8% during the 4th quarter. Beacon Capital Management LLC now owns 11,170 shares of the biopharmaceutical company's stock worth $572,000 after acquiring an additional 404 shares during the period. 67.62% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Company Profile
(Get Rating)
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Recommended Stories
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.